Home > Haematology > EHA 2019 > Lymphoid Malignancies > Brentuximab vedotin continues to demonstrate superior clinical activity in classical Hodgkin lymphoma

Brentuximab vedotin continues to demonstrate superior clinical activity in classical Hodgkin lymphoma

Presented By
Dr Steven Horwitz , Memorial Sloan Kettering Cancer Center, USA
Conference
EHA 2019
Trial
Phase 3, ECHELON-1
Additional analysis and 3-year update of results from ECHELON-1, a frontline phase 3 trial evaluating brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine (AVD) compared with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in stage III or IV frontline classical Hodgkin lymphoma (HL) patients, resulted in a statistically significant improvement in modified progression-free survival (PFS) for the brentuximab vedotin + AVD arm versus the control arm of ABVD, as assessed by independent review [1]. Brentuximab vedotin is an antibody-drug conjugate directed to CD30, a defining marker of classical HL and expressed on the surface of several types of peripheral T-cell lymphomas. The intention-to-treat analysis examined PFS outcomes per investigator assessment in the population of 1,334 patients <60 years old at 3 years, by cycle 2...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on